These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21044424)

  • 21. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward a better understanding of methotrexate.
    Kremer JM
    Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
    [No Abstract]   [Full Text] [Related]  

  • 23. Summaries for patients. Prednisone plus methotrexate for polymyalgia rheumatica.
    Ann Intern Med; 2004 Oct; 141(7):I12. PubMed ID: 15466761
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-dose and high-dose methotrexate are two different drugs in practical terms.
    Malaviya AN; Sharma A; Agarwal D; Kapoor S; Garg S; Sawhney S
    Int J Rheum Dis; 2010 Oct; 13(4):288-93. PubMed ID: 21199463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 26. Medical treatment of adolescents with rheumatic disease.
    Hollister JR
    Adolesc Med; 1998 Feb; 9(1):163-70, vii. PubMed ID: 10961259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 28. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
    Glück T; Müller-Ladner U
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
    [No Abstract]   [Full Text] [Related]  

  • 29. Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later.
    Gutiérrez-Ureña S; Espinoza LR
    Clin Exp Rheumatol; 1995; 13(3):281-4. PubMed ID: 7554552
    [No Abstract]   [Full Text] [Related]  

  • 30. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.
    Pincus T; Furer V; Sokka T
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S68-79. PubMed ID: 21044437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate for maintenance of remission in IgG4-related disease.
    Della-Torre E; Campochiaro C; Bozzolo EP; Dagna L; Scotti R; Nicoletti R; Stone JH; Sabbadini MG
    Rheumatology (Oxford); 2015 Oct; 54(10):1934-6. PubMed ID: 26139657
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate: new indication. Psoriatic arthritis: approved at last.
    Prescrire Int; 2007 Oct; 16(91):182. PubMed ID: 17926820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK Paediatric Rheumatology prescriber survey.
    Amin TS; Shenton S; Mulligan K; Wedderburn LR; Wood M; VanRooyen V; Leone V
    Rheumatology (Oxford); 2015 Nov; 54(11):2108-9. PubMed ID: 26209331
    [No Abstract]   [Full Text] [Related]  

  • 36. [Chinese expert-based consensus for methotrexate in rheumatic diseases].
    Chinese Association of Rheumatology and Immunology Physicians
    Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):719-722. PubMed ID: 30293331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate osteopathy, does it exist?
    Maenaut K; Westhovens R; Dequeker J
    J Rheumatol; 1996 Dec; 23(12):2156-9. PubMed ID: 8970056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
    Martin JJ
    Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Procedural pain and patient-reported side effects with weekly injections of subcutaneous methotrexate in children with rheumatic disorders.
    Bechard MA; Lemieux JR; Roth J; Watanabe Duffy K; Duffy CM; Aglipay MO; Jurencak R
    Pediatr Rheumatol Online J; 2014; 12():54. PubMed ID: 25584042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
    Stamp LK; Roberts RL
    Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.